Adial Pharmaceuticals, Inc.ADILNASDAQ
Loading
Operating Cash Flow Growth AcceleratingAccelerating
Percentile Rank53
Year-over-Year Change
Year-over-year operating cash flow growth rate
Percentile
P53
Within normal range
vs 3Y Ago
-1.3x
Contraction
Streak
1 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q3 2025 | -4.81% |
| Q2 2025 | -10.34% |
| Q1 2025 | -9.05% |
| Q4 2024 | 14.18% |
| Q3 2024 | 21.14% |
| Q2 2024 | -32.09% |
| Q1 2024 | -33.02% |
| Q4 2023 | 12.11% |
| Q3 2023 | 26.58% |
| Q2 2023 | 17.59% |
| Q1 2023 | -31.30% |
| Q4 2022 | 48.56% |
| Q3 2022 | 3.69% |
| Q2 2022 | -41.56% |
| Q1 2022 | -5.21% |
| Q4 2021 | 32.77% |
| Q3 2021 | -10.19% |
| Q2 2021 | -12.66% |
| Q1 2021 | -8.78% |
| Q4 2020 | -18.36% |
| Q3 2020 | -124.18% |
| Q2 2020 | 46.03% |
| Q1 2020 | -4.15% |
| Q4 2019 | -1.64% |
| Q3 2019 | -51.24% |
| Q2 2019 | 33.75% |
| Q1 2019 | -55.91% |
| Q4 2018 | -11.37% |
| Q3 2018 | -424.64% |
| Q2 2018 | 11.83% |
| Q1 2018 | -75.49% |
| Q4 2017 | 10.73% |
| Q3 2017 | 9.17% |
| Q2 2017 | -76.39% |
| Q1 2017 | -20.20% |
| Q4 2016 | 7.48% |
| Q3 2016 | -94.41% |
| Q2 2016 | 54.66% |
| Q1 2016 | 0.00% |